Showing 5571-5580 of 8473 results for "".
- Is Eli Lilly's Taltz the Next Blockbuster Drug for Psoriasis?https://practicaldermatology.com/news/is-eli-lillys-taltz-the-next-blockbuster-drug-for-psoriasis/2458569/Eli Lilly’s new psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its efficacy and good safety profile, according to an analyst at GlobalData.
- Dove Survey: Life Without Deodorant Would Be the Pitshttps://practicaldermatology.com/news/dove-survey-life-without-deodorant-would-be-the-pits/2458566/And the winner is … deodorant. Out of all the products women use in their morning beauty routine, deodorant is what makes them feel most confident– it’s twice as significant as toothpaste, four times that of foundation, nearly six times that of mascara and ten tim
- Meet Alastin's Restore & Renew Anti-Aging Linehttps://practicaldermatology.com/news/meet-alastins-restore-renew-anti-aging-line/2458570/ALASTINTM Skincare, Inc., is rolling the newest addition to their portfolio -- the Restore & Renew Anti-Aging line. The line consists of four products: the Restorative Skin ComplexTM, the Restorative Eye Tre
- New Case Study Highlights Black Henna Tattoo Riskshttps://practicaldermatology.com/news/new-case-study-highlights-black-henna-tattoo-risks/2458573/Black henna tattoos should be avoided, especially during foreign travel, UK doctors warn in BMJ Case Reports. Researchers from the University of Sheffiel
- Largest Independent US Psoriasis Registry to Track Safety of Ixekizumab Biologic Treatmenthttps://practicaldermatology.com/news/largest-independent-us-psoriasis-registry-to-track-safety-of-ixekizumab-biologic-treatment/2458583/The Corrona Psoriasis Registry will track the drug safety reporting for ixekizumab, Eli Lilly and Company's biologic medication that was recently approved for the treatment of moderate-to-severe plaque psoriasis. The registry is a joint collaboration between the National Psoriasis Foundation
- Study: Viveve® Improves Vaginal Laxityhttps://practicaldermatology.com/news/study-viveve-improves-vaginal-laxity/2458595/The Viveve System improves vaginal laxity when compared with a sham procedure, a new study suggests. Top-line results from the VIveve Treatment of the Vaginal Introitus to EValuate Efficacy (VIVEVE 1) show that the procedure is both safe and effec
- CeraVe® Named Official Skincare Sponsor of LPGA Golf Clinics for Womenhttps://practicaldermatology.com/news/cerave-named-official-skincare-sponsor-of-lpga-golf-clinics-for-women/2458599/CeraVe® skincare products, thave been named Official Skincare Partner of the Ladies Professional Golf Association (LPGA) Golf Clinics for Women, reports Valeant <
- Phat Lips: Celebrity Lip Envy Driving Explosive Growth in Lip Enhancementhttps://practicaldermatology.com/news/phat-lips-celebrity-lip-envy-driving-explosive-growth-in-lip-enhancement/2458605/Someone gets their lips enhanced every 19 minutes in the US, the American Society of Plastic Surgeons (ASPS) reports. And a new ASPS survey suggests that celebrity lip envy may be driving this trend. The most likeable lips belong to Jennif
- Study on TRASER for Nasal Spider Veins Scores Top Honors from ASLMShttps://practicaldermatology.com/news/study-on-traser-for-nasal-spider-veins-scores-top-honors-from-aslms/2458606/Houston dermatologist Paul M. Friedman, MD won the Best of Cutaneous Applications Abstract Session Award for his paper on the use of a novel optical device to treat vexing nasal telangiectasias. The award was presented at the 2016 Annual Conference of the American S
- Galderma's New #BreakTheIce Campaign Debunks the Fear of Frozen Lookhttps://practicaldermatology.com/news/galdermas-new-breaktheice-campaign-debunks-the-fear-of-frozen-look/2458612/When it comes to facial rejuvenation, fresh is the new frozen. Fully 74 percent of women and men aged 30-50 would be more interested in anti-aging treatments if results looked natural, according to new survey commissioned by Galderma Laborator